AMBER VIEL: Open Payments
NPI 1083987317 · WHITE MARSH, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,387 in 64 payments from 15 companies in 2025. Trend: 2023 $1,408 · 2024 $1,591 · 2025 $1,387
Food & beverage: $1,387
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 14 | $287 |
| AstraZeneca Pharmaceuticals LP | 9 | $230 |
| Regeneron Healthcare Solutions, Inc. | 10 | $198 |
| Genentech USA, Inc. | 6 | $138 |
| Novartis Pharmaceuticals Corporation | 5 | $119 |
| GENZYME CORPORATION | 5 | $101 |
| Amgen Inc. | 4 | $80 |
| ABBVIE INC. | 2 | $53 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $41 |
| Organon LLC | 2 | $29 |
Products named: DUPIXENT, FASENRA, NUCALA, Xolair, TRELEGY ELLIPTA, TEZSPIRE, RINVOQ, Rhapsido.
Industry payments across MD — which companies pay providers there.
